Who Owns Vaseretic?

Who owns Bausch Health?
Bausch Health Companies Inc. is a publicly traded company listed on the NYSE and TSX under ticker BHC, with 370,562,428 shares outstanding as of February 13, 2026. The company has a dispersed shareholder base with institutional investors holding the majority of shares and no single controlling shareholder. The aggregate market value of common shares held by non-affiliates was approximately $2 billion as of June 30, 2025.

What is Bausch Health's annual revenue?
Bausch Health reported consolidated revenue of $10.27 billion for fiscal year 2025, an increase of 7% on a reported basis and 5% on an organic basis compared to FY2024. GAAP net income attributable to Bausch Health was $157 million, and Consolidated Adjusted EBITDA was $3.54 billion, up 7%. For Q2 2026, consolidated revenue was $2.85 billion, up 13%, and the company raised its full-year 2026 guidance.

What brands does Bausch Health own?
Bausch Health owns Salix Pharmaceuticals (gastroenterology, including Xifaxan and Trulance), Solta Medical (aesthetic devices including Thermage and Fraxel), Ortho Dermatologics (dermatology pharmaceuticals), and DURERT Corporation (hepatology, acquired 2025). The company also holds approximately 88% ownership of Bausch + Lomb Corporation (NYSE: BLCO), a leading eye health brand for contact lenses, intraocular lenses, and ophthalmic surgical equipment.

Is Bausch Health the same as Valeant?
Yes, Bausch Health was formerly known as Valeant Pharmaceuticals International. The company changed its name to Bausch Health Companies Inc. in 2018 to distance itself from the controversies of the Valeant era, including the Philidor Rx Services scandal, drug pricing investigations, and accounting restatements that caused the stock price to collapse from approximately $263 to under $20 per share between 2015 and 2016.

What is Xifaxan and why is it important to Bausch Health?
Xifaxan (rifaxmin) is a gastroenterology drug used to treat irritable bowel syndrome with diarrhea and hepatic encephalopathy. It is Bausch Health's largest product and the primary revenue driver in the Salix segment, with 26% revenue growth in Q2 2026. Patent litigation has blocked generic competition until at least 2029, with an appeals court affirming the FDA's block of Norwich Pharmaceuticals' generic in June 2026. However, Xifaxan has been selected for CMS drug price negotiation under the Inflation Reduction Act, with initial price applicability in 2027.

What is the Bausch + Lomb separation?
Bausch Health announced in August 2020 its plan to separate its eye health business (Bausch + Lomb) into an independent publicly traded entity. Bausch + Lomb completed its IPO in May 2022 (NYSE: BLCO), with Bausch Health retaining approximately 88% ownership. The full separation, which may include monetizing Bausch Health's ownership interest or transferring equity to shareholders, remains subject to achieving targeted debt leverage ratios and receiving necessary approvals. No definitive timeline has been provided as of 2026.

How much debt does Bausch Health have?
Bausch Health carries a substantial debt load from its Valeant-era acquisition strategy. In 2025, the company completed $9.6 billion in total debt refinancing, including a $1.7 billion debt exchange offer in Q4 2025, extending near- and medium-term maturities. The debt burden has been a primary constraint on financial flexibility and has delayed the full separation of Bausch + Lomb. The company generated $1.2 billion in Adjusted Cash Flow from Operations in FY2025.

Who is the CEO of Bausch Health?
Thomas J. Appio serves as Chief Executive Officer of Bausch Health Companies Inc. Under his leadership, the company has delivered thirteen consecutive quarters of year-over-year growth in both Revenue and Adjusted EBITDA for Bausch Health excluding Bausch + Lomb, as of Q2 2026. Appio has focused on commercial and operational excellence, strategic acquisitions, and proactive debt management.